Abstract：
UNASSIGNED: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part I of a three-part series focusing on treatment decision-making at the time of suspected biochemical recurrence (BCR) after radical prostatectomy (RP). Please refer to Part II for discussion of treatment delivery for non-metastatic BCR after RP and Part III for discussion of evaluation and management of recurrence after radiotherapy (RT) and focal therapy, regional recurrence, and oligometastasis.
UNASSIGNED: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles.
UNASSIGNED: In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Panel developed evidence- and consensus-based statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease.
UNASSIGNED: Advancing work in the area of diagnostic tools (particularly imaging), biomarkers, radiation delivery, and biological manipulation with the evolving armamentarium of therapeutic agents will undoubtedly present new opportunities for patients to experience long-term control of their cancer while minimizing toxicity.
UNASSIGNED: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles.
UNASSIGNED: In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Panel developed evidence- and consensus-based statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease.
UNASSIGNED: Advancing work in the area of diagnostic tools (particularly imaging), biomarkers, radiation delivery, and biological manipulation with the evolving armamentarium of therapeutic agents will undoubtedly present new opportunities for patients to experience long-term control of their cancer while minimizing toxicity.
摘要：
本文提供的概述涵盖了关于复发性前列腺癌的挽救治疗的建议，旨在促进护理决策并帮助临床医生照顾在具有治愈意图的先前治疗后经历复发的患者。这是一个由三部分组成的系列的第一部分，重点是前列腺癌根治术（RP）后可疑生化复发（BCR）时的治疗决策。关于RP后非转移性BCR的治疗实施，请参阅第二部分；关于放疗（RT）和局灶治疗后复发的评估和处理，请参阅第三部分。区域性复发，和寡转移。
■通知本指南的系统评价是基于OvidMEDLINE中的搜索（1946年至2022年7月21日），Cochrane中央受控试验登记册（至2022年8月），和Cochrane系统评价数据库(至2022年8月)。更新搜索于2023年7月26日进行。通过审查相关文章的电子数据库参考清单来补充搜索。
■在AUA之间的合作努力中，ASTRO,而SUO,前列腺癌的挽救治疗小组制定了基于证据和共识的声明,为在临床局部疾病的初始确定局部治疗后经历BCR的患者的护理提供指导.
■推进诊断工具（尤其是成像）领域的工作，生物标志物，辐射输送，和生物操作与不断发展的医疗药物无疑将为患者提供新的机会，以体验他们的癌症的长期控制，同时尽量减少毒性。
■通知本指南的系统评价是基于OvidMEDLINE中的搜索（1946年至2022年7月21日），Cochrane中央受控试验登记册（至2022年8月），和Cochrane系统评价数据库(至2022年8月)。更新搜索于2023年7月26日进行。通过审查相关文章的电子数据库参考清单来补充搜索。
■在AUA之间的合作努力中，ASTRO,而SUO,前列腺癌的挽救治疗小组制定了基于证据和共识的声明,为在临床局部疾病的初始确定局部治疗后经历BCR的患者的护理提供指导.
■推进诊断工具（尤其是成像）领域的工作，生物标志物，辐射输送，和生物操作与不断发展的医疗药物无疑将为患者提供新的机会，以体验他们的癌症的长期控制，同时尽量减少毒性。
